Search Results

• SPINEJACK IN LIEU OF FORMAL CORPECTOMY CAGES: A CASE SERIES

  SpineJack in lieu of Formal Corpectomy Cages: A Case Series

• A novel wearable system for monitoring and alerting for seizures and cardiorespiratory dysfunctions

  A novel wearable system for monitoring and alerting for seizures and cardiorespiratory dysfunctions

• A Retrospective Assessment of Novel Biomarkers Indicating Intestinal Inflammation and Intestinal Permeability, Identified During Non-Invasive Leaky Gut Testing

  A Retrospective Assessment of Novel Biomarkers Indicating Intestinal Inflammation and Intestinal Permeability, Identified During Non-Invasive Leaky Gut Testing

• A Multicenter, Open-Label, Pharmacokinetic and Safety Study of Baricitinib in Pediatric Patients from 1 Year to Less Than 18 Years Old Hospitalized with COVID-19

  A Multicenter, Open-Label, Pharmacokinetic and Safety Study of Baricitinib in Pediatric Patients from 1 Year to Less Than 18 Years Old Hospitalized

• Open-Label Induction, Randomized Double-Blind Maintenance, and Long-Term Extension Periods in Pediatric Subjects (2 to < 18 Years of Age) with Moderately to Severely Active Crohn's Disease

  A Phase 3, Multi-Center Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Risankizumab with Open-Label Induction, Randomized

• A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Safety and Efficacy of Tenapanor for the Treatment of IBS-C in Pediatric Patients 12 to 18 Years Old

  A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Safety and Efficacy of Tenapanor for the Treatment of Irritable

• A 4-Week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Safety and Efficacy of Tenapanor for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C) in Pediatric Patients 6 to Less than 12 Years Old

  A 4-Week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Safety and Efficacy of Tenapanor for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C) in Pediatric Patients 6 to Less than 12 Years Old